CMP-5 (PRMT5-IN-5) is a first-in-class and specific PRMT5 inhibitor with anticancer (B-cell lymphomas) and immunomodulatory activity. It displays no activity against other type I (PRMT1 and PRMT4) and type II (PRMT7) enzymes. CMP-5 blocks EBV-driven B-lymphocyte transformation and survival, without effect on normal B cells. Inhibition of PRMT5 leads to lost recruitment of a PRMT5/p65/HDAC3-repressive complex on the miR96 promoter, restored miR96 expression, and PRMT5 downregulation.

纯度：≥98%

CAS：880813-42-3